pioneering next generation approaches to cure neurological conditions.
pioneering next generation approaches to cure neurological conditions.
RECENT NEWS
Kenai Therapeutics Appoints Rekha Hemrajani to Board of Directors
Kenai Therapeutics Inc., a clinical-stage biotechnology company pioneering next-generation approaches to cure neurological conditions, today announced the appointment of Rekha Hemrajani to the company’s Board of Directors… CONTINUE READING
VIEW ALL PRESS RELEASES


meet kenai therapeutics
We are a clinical-stage biotechnology company advancing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for the treatment of neurological conditions. Our aim is to deliver disease-modifying and potentially curative treatments that go beyond symptom management to reverse the impact of neurodegeneration – with the goal of restoring quality of life.
